• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.格拉司琼单药与格拉司琼联合地塞米松预防细胞毒性药物所致呕吐的比较。
Br J Cancer. 1994 Dec;70(6):1161-4. doi: 10.1038/bjc.1994.465.
2
Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.口服格拉司琼加地塞米松与静脉注射昂丹司琼加地塞米松控制中/重度致吐性化疗引起的恶心和呕吐的疗效及安全性比较。
Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):729-36.
3
Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.格拉司琼联合地塞米松或单独使用地塞米松对接受高致吐性化疗患者延迟性恶心和呕吐的控制:一项双盲、安慰剂对照的比较研究。
Ann Oncol. 1998 Jun;9(6):661-6. doi: 10.1023/a:1008256115221.
4
A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy.一项双盲交叉研究,比较单独使用预防性静脉注射格拉司琼或联合地塞米松作为止吐治疗,以控制与化疗相关的恶心和呕吐。
Eur J Cancer. 1997 Sep;33(10):1605-10. doi: 10.1016/s0959-8049(97)00160-3.
5
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.一项比较肌肉注射格拉司琼与肌肉注射格拉司琼加地塞米松预防顺铂所致迟发性呕吐的双盲随机研究。意大利多中心研究组。
Anticancer Drugs. 1999 Jun;10(5):465-70.
6
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.单剂量口服格拉司琼与静脉注射昂丹司琼预防中度致吐性化疗引起的恶心和呕吐的比较:一项多中心、双盲、随机平行研究。
J Clin Oncol. 1998 Feb;16(2):754-60. doi: 10.1200/JCO.1998.16.2.754.
7
Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.三种止吐方案在接受中度致吐性化疗患者中的疗效持久性及预后因素。意大利止吐研究小组
J Clin Oncol. 1995 Sep;13(9):2417-26. doi: 10.1200/JCO.1995.13.9.2417.
8
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.三联方案止吐疗法对接受高致吐性化疗的骨肉瘤和软组织肉瘤患者化疗引起的恶心和呕吐(CINV)的疗效,以及在一项随机、单盲交叉研究中,单次注射帕洛诺司琼和连续数日使用格拉司琼对CINV疗效的比较。
Cancer Med. 2015 Mar;4(3):333-41. doi: 10.1002/cam4.373. Epub 2014 Dec 23.
9
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.低剂量口服格拉司琼加地塞米松与高剂量甲氧氯普胺加地塞米松预防年轻非霍奇金淋巴瘤患者CHOP化疗所致恶心呕吐的比较研究
J Med Assoc Thai. 2002 Nov;85(11):1156-63.
10
Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.格拉司琼加地塞米松口服混悬液的止吐疗效及生活质量对恶心和呕吐风险的影响。
Onkologie. 2005 Feb;28(2):88-92. doi: 10.1159/000082523.

引用本文的文献

1
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.乳腺癌患者化疗所致恶心呕吐的止吐治疗选择。
Breast Cancer (Dove Med Press). 2011 Nov 14;3:151-60. doi: 10.2147/BCTT.S12955.
2
Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial.两种剂量(1 毫克和 3 毫克)格拉司琼静脉给药预防化疗引起的急性呕吐的比较试验:一项双盲、随机、非劣效性试验。
Support Care Cancer. 2012 May;20(5):1057-64. doi: 10.1007/s00520-011-1185-x. Epub 2011 May 18.
3
Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis.雷莫司琼联合地塞米松与单用雷莫司琼控制顺铂所致呕吐的多中心随机试验
Support Care Cancer. 2004 Jan;12(1):58-63. doi: 10.1007/s00520-003-0528-7. Epub 2003 Dec 4.
4
Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.格拉司琼。对其用于预防化疗引起的恶心和呕吐的药物经济学评价。
Pharmacoeconomics. 1996 Apr;9(4):357-74. doi: 10.2165/00019053-199609040-00009.
5
Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.地塞米松剂量联合5-羟色胺3受体拮抗剂在预防急性化疗所致恶心和呕吐中的作用
Br J Cancer. 1999 Feb;79(3-4):637-9. doi: 10.1038/sj.bjc.6690100.
6
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.单次大剂量地塞米松可提高昂丹司琼对急性化疗引起的恶心和呕吐的疗效,但会削弱对延迟症状的控制。
Support Care Cancer. 1996 Nov;4(6):440-6. doi: 10.1007/BF01880642.
7
New perspectives in antiemetic treatment.止吐治疗的新视角。
Support Care Cancer. 1996 Nov;4(6):416-9. doi: 10.1007/BF01880638.
8
Impact of tumour burden on chemotherapy-induced nausea and vomiting.肿瘤负荷对化疗所致恶心和呕吐的影响。
Br J Cancer. 1996 Oct;74(7):1114-9. doi: 10.1038/bjc.1996.499.
9
Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.格拉司琼。其在抗肿瘤治疗引起的恶心和呕吐治疗应用方面的最新进展。
Drugs. 1994 Nov;48(5):761-93. doi: 10.2165/00003495-199448050-00008.

本文引用的文献

1
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.急性顺铂所致呕吐的控制——格拉司琼与大剂量甲氧氯普胺和地塞米松联合方案的比较研究。格拉司琼研究组。
Br J Cancer. 1993 Jul;68(1):176-80. doi: 10.1038/bjc.1993.309.
2
Antiemetic therapy--where do we go from here?抗呕吐治疗——我们从这里走向何方?
Ann Oncol. 1993 Jun;4(6):443-5. doi: 10.1093/oxfordjournals.annonc.a058547.
3
Antiemetic drug combinations in advanced cancer.晚期癌症中的止吐药物联合应用
Lancet. 1982 May 1;1(8279):1018. doi: 10.1016/s0140-6736(82)92015-3.
4
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.两种不同高剂量胃复安对顺铂治疗的癌症患者的止吐活性:意大利临床研究肿瘤学组的一项随机双盲试验
Cancer Treat Rep. 1985 Dec;69(12):1353-7.
5
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
J Clin Oncol. 1989 Jan;7(1):108-14. doi: 10.1200/JCO.1989.7.1.108.
6
A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.一项关于使用选择性5-羟色胺3(5-HT3)拮抗剂格拉司琼与使用氯丙嗪加地塞米松的标准止吐方案治疗细胞抑制剂引起的呕吐的对比研究。格拉司琼研究小组。
Eur J Cancer. 1990;26 Suppl 1:S28-32.
7
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.昂丹司琼与大剂量甲氧氯普胺预防顺铂所致急性和迟发性恶心呕吐的比较。一项多中心、随机、双盲、交叉研究。
Ann Intern Med. 1990 Dec 1;113(11):834-40. doi: 10.7326/0003-4819-113-11-834.
8
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?地塞米松是否能增强昂丹司琼对顺铂所致急性呕吐的控制作用?
BMJ. 1991 Dec 7;303(6815):1423-6. doi: 10.1136/bmj.303.6815.1423.
9
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
J Clin Oncol. 1991 Apr;9(4):675-8. doi: 10.1200/JCO.1991.9.4.675.
10
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Lancet. 1991 Aug 24;338(8765):483-7. doi: 10.1016/0140-6736(91)90554-3.

格拉司琼单药与格拉司琼联合地塞米松预防细胞毒性药物所致呕吐的比较。

Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.

作者信息

Carmichael J, Bessell E M, Harris A L, Hutcheon A W, Dawes P J, Daniels S, Bessel E M

机构信息

CRC Academic Unit of Clinical Oncology, Nottingham City Hospital Trust, UK.

出版信息

Br J Cancer. 1994 Dec;70(6):1161-4. doi: 10.1038/bjc.1994.465.

DOI:10.1038/bjc.1994.465
PMID:7981069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2033694/
Abstract

Two hundred and seventy-eight adult chemonaive patients, receiving moderately emetogenic chemotherapy were randomly allocated to receive either intravenous (i.v.) granisetron 3 mg plus i.v. dexamethasone 8 mg or i.v. granisetron 3 mg plus i.v. placebo dexamethasone prior to chemotherapy. Eight-two per cent of all patients recruited were female, and 91% of all patients consumed less than 10 units of alcohol per week, suggesting a study population with an increased risk of nausea and vomiting. In the first 24 h 85% of patients who received granisetron plus dexamethasone were complete responders compared with 75.9% of the patients receiving granisetron alone (P = 0.053). There were statistically significant improvements in complete response over 7 days (P = 0.029) and in the numbers of patients receiving rescue antiemetic (P = 0.0004). Toxicity was minimal with no significant differences between treatment groups. These results confirm the antiemetic activity of granisetron and show that it has an additive effect in combination with dexamethasone.

摘要

278名未曾接受过化疗的成年患者接受中度致吐性化疗,在化疗前被随机分配接受静脉注射3毫克格拉司琼加静脉注射8毫克地塞米松,或静脉注射3毫克格拉司琼加静脉注射安慰剂地塞米松。所有招募患者中82%为女性,91%的患者每周饮酒量少于10个单位,这表明研究人群恶心和呕吐风险增加。在最初24小时内,接受格拉司琼加地塞米松的患者中85%为完全缓解者,而仅接受格拉司琼的患者为75.9%(P = 0.053)。在7天内完全缓解率有统计学显著改善(P = 0.029),接受解救性止吐药治疗的患者数量也有统计学显著改善(P = 0.0004)。毒性极小,治疗组之间无显著差异。这些结果证实了格拉司琼的止吐活性,并表明它与地塞米松联合使用有相加作用。